3 completed, 2 recruiting, 2 terminated, 1 unknown. 4 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Sickle Cell Disorders: new trials by email Literature Review of Sickle Cell Disorders trials Research Report on Sickle Cell Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease Fostamatinib - Sickle Cell Disorders, Sickle Cell Disease | Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 35 | 2024-12-18 | 2026-11-02 |
| A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation, Matched sibling donor transplantation - HbS Disease, Hemoglobin S Disease | Phase 2 | Recruiting | University of Regensburg | 212 | 2021-06-30 | 2024-05-13 |
| GenoMed4ALL: Improving SCD Classification and Prognosis by AI Sickle Cell Disorders | Unknown | Hospital Universitari Vall d'Hebron Research Institute | 1000 | 2021-01-01 | 2024-04-12 | |
| To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease AXA4010 - To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease, Anemia, Sickle Cell | Not applicable | Completed | Axcella Health, Inc | 9 | 2019-09-25 | 2021-04-01 |
| Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease Rivipansel - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Terminated | GlycoMimetics Incorporated | 154 | 2015-12-16 | 2021-02-10 |
| Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis MP4CO, Sodium chloride solution - Anemia, Sickle Cell, Sickle Cell Anemia | Phase 2 | Withdrawn | Sangart | 2013-10-01 | 2013-10-28 | |
| Effects of HQK-1001 in Patients With Sickle Cell Disease HQK-1001, Placebo - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Terminated | HemaQuest Pharmaceuticals Inc. | 77 | 2012-07-01 | 2015-03-18 |
| Safety Study of MP4CO in Adult Sickle Cell Patients MP4CO, Sodium chloride solution - Anemia, Sickle Cell, Sickle Cell Anemia | Phase 1 | Completed | Sangart | 32 | 2012-01-01 | 2013-08-19 |
| A Study of HQK-1001 in Patients With Sickle Cell Disease HQK-1001 - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Completed | HemaQuest Pharmaceuticals Inc. | 52 | 2011-04-01 | 2013-06-19 |
Anemia, Sickle Cell (9) · Vaso-Occlusive Crises (3) · Hemoglobin SC Disease (2) · Hematologic Diseases (1) · Sickle Cell Trait (1)
Anemia (9) · Anemia, Hemolytic (9) · Anemia, Hemolytic, Congenital (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Hemic and Lymphatic Diseases (9) · Hemoglobinopathies (9) · Hematologic Diseases (8)
2,2-dimethylbutyric acid (2) · PEGylated carboxyhemoglobin bovine (2) · Saline Solution (2) · Sodium Chloride (2) · fostamatinib (1) · rivipansel (1)
HemaQuest Pharmaceuticals Inc. (2) · Sangart (2) · Axcella Health, Inc (1) · GlycoMimetics Incorporated (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · University of Regensburg (1)
United States (5) · Lebanon (4) · Canada (3) · France (3) · Jamaica (3) · Egypt (2) · Netherlands (2) · United Kingdom (2) · Austria (1) · Bahrain (1) · Belgium (1) · Brazil (1) · Germany (1) · Italy (1) · Qatar (1)
Richard Ghalie, MD, MBA (2) · Tania Small, MD (2) · Eduard van Beers (1) · Federico Alvarez (1) · Gastone Castellani (1) · Kimberly Cruz, MD (1) · Marianne de Montalembert (1) · Matteo Della Porta (1) · Pablo Bartolucci (1) · Petros Kountouris (1) · Raffaella Colombatti (1) · Selim Corbacioglu, MD (1) · Swee Lay Thein, M.D. (1)